Omega Fatty Acid Supplements Fail to Ease Autism Behaviors in Rigorous Child Trial

A carefully controlled clinical trial has delivered a sobering verdict on one of the most popular dietary interventions for autism: daily supplementation with omega-3 and omega-6 fatty acids did not reduce inflammatory markers or improve autism-related behaviors in young children. The study, known as the second Omega Heroes trial, was conducted at Nationwide Children’s Hospital in Columbus, Ohio, and published in the Journal of Autism and Developmental Disorders. Its findings strike directly at a widely held hypothesis that inflammation is a key mechanism linking fatty acids to changes in autism features, and they suggest that families spending money on fish and borage oil supplements for this purpose may be getting little in return.

Autism affects roughly one in 31 children aged 8 in the United States, yet no medications are specifically approved to support this population. The pharmacological options that do exist, such as atypical antipsychotics prescribed for irritability and self-injury, carry significant side effects. Behavioral programs remain the most effective support for daily functioning, but they are intensive, costly, and out of reach for many families. Against this backdrop, complementary strategies like polyunsaturated fatty acid supplements have flourished, even though the evidence for their efficacy has long been mixed. Prior trials were often small, unblinded, or inconsistent in the doses and fatty acid combinations they tested, leaving families and clinicians without clear guidance.

The scientific rationale for the trial rested on a plausible biological story. Elevated inflammation is well documented in children with autism, both in the peripheral bloodstream and in cerebrospinal fluid, and meta-analyses have confirmed a general state of heightened pro-inflammatory signaling in autistic individuals. Omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), along with the omega-6 fatty acid gamma-linolenic acid (GLA), are known to have anti-inflammatory properties. The researchers hypothesized that a combination of DHA, EPA, and GLA would amplify these anti-inflammatory effects, dampen systemic and neuroinflammation, and thereby improve autism-related behaviors. An earlier Omega Heroes trial had reported that the same supplement reduced interleukin-2 levels compared with placebo, and observational work had suggested benefits to social communication and adaptive behavior.

To test this rigorously, the team enrolled 98 children between 2 and just under 7 years old who had been diagnosed with autism within the previous six months at a multidisciplinary autism clinic. Diagnoses were based on comprehensive evaluations covering all DSM-5 criteria, cognitive ability, and adaptive behavior. Children were randomly assigned in a double-blind design to receive either the active supplement, a lemon-flavored fish and borage oil providing 100 milligrams per kilogram of body weight per day of combined GLA, EPA, and DHA, or a matching lemon-flavored canola oil placebo. Randomization was stratified by age and sex, and everyone involved, from investigators to caregivers to children, remained blinded to group assignment throughout the 90-day trial.

The researchers measured a panel of inflammatory cytokines in plasma at baseline and at the end of the trial, focusing on interleukin-1 beta, interleukin-2, and tumor necrosis factor alpha as primary markers, with interferon gamma, interleukin-6, and interleukin-8 measured for exploratory purposes. Autism-related behaviors were assessed through both caregiver report and direct evaluation by trained psychometrists, using instruments including the PDD Behavior Inventory, the Vineland Adaptive Behavior Scales, the Autism Impact Measure, the Childhood Autism Rating Scale, and the Preschool Language Scales. Red blood cell fatty acid levels were also analyzed to confirm that the supplement was actually being absorbed.

The results were largely null. Of the 96 children included in the analysis, those receiving omega 3-6 supplementation showed no meaningful differences in cytokine changes compared with the placebo group. The supplement was clearly bioavailable, as children in the active group showed significant increases in red blood cell EPA and DHA, yet these biological shifts did not translate into reduced inflammation or behavioral improvement. Changes in cytokines were generally uncorrelated with changes in autism-related behaviors and features across the full sample. On the primary behavioral outcome, the PDDBI autism composite, the difference in change between groups was just 0.1 points, with a confidence interval spanning from minus 10.9 to plus 11.1, a range that comfortably includes no effect.

The trial did not replicate the earlier finding that the supplement lowered interleukin-2, and the authors acknowledge several possible reasons for the discrepancy and the largely null results. The dose or combination of fatty acids may have been suboptimal, the sample of 96 children may have been too small to detect modest effects, the heterogeneity of autism features among participants may have obscured patterns, and compliance was imperfect, with diary data indicating children consumed about 65 percent of the dispensed product. Compliance was similar between groups, however, and adverse events, most commonly gastrointestinal or appetite-related symptoms, were equally distributed and none were judged serious and related to the investigational products.

One of the more intriguing findings emerged from exploratory analyses of sex differences. Sex significantly moderated the effect of supplementation on several outcomes, though the pattern was unexpected. Females assigned to placebo fared better than females assigned to omega 3-6 on measures including PDDBI aggressiveness, Vineland communication and socialization, and repetitive behaviors, while males in the active group showed improvement in adaptive behavior composite scores relative to males on placebo. The authors caution that the trial was not powered for subgroup analyses and that all sex-differentiated outcomes came from caregiver report, raising the possibility that parents rated behaviors differently for daughters than for sons. Still, the finding adds to a long scientific conversation about why autism presents and is diagnosed differently in males and females, from diagnostic masking to hormonal influences during development.

The study’s strengths are considerable. Its double-blind, randomized, placebo-controlled design minimizes bias, the sample was larger than most prior fatty acid trials in autism, retention was high, and randomization was stratified by sex and age. The focus on early childhood was deliberate, since neuroplasticity declines with age and DHA accretion in the developing brain slows correspondingly, meaning early intervention offers the best theoretical window. The outcome measures were chosen specifically for their sensitivity to behavioral change over time, addressing a known weakness of standard autism diagnostic instruments. The sample also reflected the racial and ethnic diversity of the local population.

Limitations temper the conclusions. Peripheral blood cytokines may not accurately reflect inflammatory processes within the central nervous system, so the null results cannot definitively rule out neuroinflammation as a mechanism. The 90-day duration, while consistent with prior fatty acid trials, is short compared with intensive behavioral programs, and the age range and single-site design limit generalizability to older children, non-English-speaking families, or those with subclinical traits. The authors suggest that future trials might test different doses, longer durations, or alternative biological signatures of supplementation. For now, the message for families is measured: this rigorous trial offered little support for inflammation as the pathway by which omega fatty acids influence autism-related behaviors in young children, and the suggestive sex-specific effects deserve replication in larger studies before anyone changes practice.

Subject of Research: The effect of omega-3 and omega-6 fatty acid supplementation on inflammatory cytokines and autism-related behaviors in young children

Article Title: Inflammatory Cytokines as Biologic Signatures of the Effect of Dietary Supplementation With Omega Fatty Acids on Autism-Related Behaviors and Features Among Young Children: A Randomized Controlled Trial

Article References: Keim, S. A., Rausch, J., Coury, D. L., Robinette, L. M., Taylor, P. L., Sun, L., McNally, K. A., & Rogers, L. K. (2026). Inflammatory Cytokines as Biologic Signatures of the Effect of Dietary Supplementation With Omega Fatty Acids on Autism-Related Behaviors and Features Among Young Children: A Randomized Controlled Trial. Journal of Autism and Developmental Disorders. https://doi.org/10.1007/s10803-026-07523-w

Image Credits: AI Generated

DOI: 10.1007/s10803-026-07523-w

Keywords: autism, omega-3 fatty acids, omega-6 fatty acids, cytokines, inflammation, randomized controlled trial, DHA, EPA, GLA, neuroinflammation, pediatrics, dietary supplements